Aptar Pharma has acquired Pulmotree, a Munich-based company developing pulmonary drug delivery systems, adding a non-propellant inhaler platform to its respiratory device portfolio.
The acquisition centers on Pulmotree’s Kolibri platform, which is designed to deliver medicines to the lungs, including complex molecules such as biologics. Aptar said it intends to support the platform’s development, manufacturing scale-up and commercialization.
The deal follows an exclusive collaboration agreement established between the companies in 2024. During that partnership, pharmaceutical companies evaluated and gained hands-on experience with Kolibri, according to Jonathan Mulpas, Aptar Pharma’s director of business development for its pulmonary category.
Kolibri uses a breath-triggered vibrating mesh to generate an aerosol. Its breath-guidance features are designed to support targeted delivery within the lungs. The device also incorporates connectivity features intended to support treatment monitoring and the collection of information about therapy use.
Non-propellant liquid inhalers include nebulizers and soft-mist inhalers. These systems are being developed as alternatives to inhalers that rely on propellants, the companies said.
Aptar plans to combine Pulmotree’s technology with its formulation, device development, regulatory and manufacturing services to support pharmaceutical customers through clinical evaluation and potential market launch.